Haematologica丨ANCHOR Study: Dose Exploration of Melflufen Combined with Multi-Drug Therapy in Relapsed/Refractory Multiple Myeloma

Haematologica丨ANCHOR Study: Dose Exploration of Melflufen Combined with Multi-Drug Therapy in Relapsed/Refractory Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy and is a disease of terminally differentiated plasma cells. As MM progresses, treatment becomes increasingly difficult, and the periods of remission after each relapse grow shorter. There is an urgent need for new therapeutic combinations that can provide deeper and more durable responses. Recently, Haematologica published the final results of the phase I/IIa ANCHOR study, which investigated the efficacy and safety of the novel alkylating peptide-drug conjugate melflufen flufenamide (melflufen) in combination with dexamethasone and either daratumumab or bortezomib for the treatment of relapsed/refractory MM.
Venetoclax±BTKi-Based Chemotherapy as a Potential Bridging Therapy Before CAR-T Treatment for Relapsed/Refractory B-Cell Lymphoma

Venetoclax±BTKi-Based Chemotherapy as a Potential Bridging Therapy Before CAR-T Treatment for Relapsed/Refractory B-Cell Lymphoma

The efficacy of CAR-T therapy in B-cell lymphoma is increasingly recognized, and its real-world application is expanding. However, patients with high tumor burden face a high incidence of cytokine release syndrome (CRS) and poor outcomes, leading to high treatment-related mortality. There is an urgent need for effective bridging therapies to reduce CRS incidence and improve remission rates in relapsed/refractory B-cell lymphoma patients. From June 13-16, 2024, the 29th European Hematology Association (EHA) Annual Meeting will take place. Dr.  Rui Liu, head of the research team of Professors Xiaoyan Ke and Kai Hu from Beijing Gaobo Hospital, will present a poster titled “VENETOCLAX AND BTK INHIBITORS BASED CHEMOTHERAPY IS A POTENTIAL EFFECTIVE CAR-T BRIDGING THERAPY IN R/R B-NHL,” offering new insights into bridging therapies before CAR-T for relapsed/refractory B-cell lymphoma.
Lancet Haematol丨HOPE-B Trial: Long-Term Follow-Up Results of Gene Therapy for Hemophilia B

Lancet Haematol丨HOPE-B Trial: Long-Term Follow-Up Results of Gene Therapy for Hemophilia B

Hemophilia B is characterized by a deficiency in clotting factor IX due to mutations in the F9 gene, impairing coagulation and increasing bleeding risk. Predominantly affecting males, hemophilia B can be classified as mild (factor IX activity >5% and <40% of normal levels), moderate (1%-5%), or severe (<1%). The primary clinical manifestation is bleeding, most commonly musculoskeletal bleeding, which can lead to severe joint disease and significantly impact the quality of life.
JCO丨EURO-SKI Study: Final Analysis and New Prognostic Factors for Treatment-Free Remission in CML

JCO丨EURO-SKI Study: Final Analysis and New Prognostic Factors for Treatment-Free Remission in CML

For chronic myeloid leukemia (CML) patients who achieve deep and durable molecular remission, the feasibility of discontinuing tyrosine kinase inhibitors (TKIs) has been established, challenging the notion of lifelong dependency on TKIs. Achieving treatment-free remission (TFR) without affecting overall survival (OS) is a key objective in current CML treatment. Recently, the Journal of Clinical Oncology (JCO) published the three-year follow-up results of the EURO-SKI study, providing a final analysis of prognostic factors related to TFR. Here, we present a summary of the findings from this comprehensive study.
ASCO China Voice | Two Studies by Professor Jiayu Wang from Academician Binghe Xu’s Team Selected for ASCO

ASCO China Voice | Two Studies by Professor Jiayu Wang from Academician Binghe Xu’s Team Selected for ASCO

The 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) will be held from May 31 to June 4 in Chicago, Eastern Time. Two studies led by Professor Jiayu Wang from Academician Binghe Xu's team at the Cancer Hospital of the Chinese Academy of Medical Sciences (CAMS) have been selected for poster presentation at the ASCO Annual Meeting. This article introduces these studies (Abstract Numbers: 1058, 3117).
Bearing Responsibility and Taking on Challenges—ILROG Leading the Future of the Lymphoma Field

Bearing Responsibility and Taking on Challenges—ILROG Leading the Future of the Lymphoma Field

With the rapid development of medical technology, modern lymphoma treatment has become a key focus in the field of oncology. From May 25 to 26, the Modern Lymphoma Treatment Academic Conference and the 5th International Lymphoma Radiation Oncology Group (ILROG) Continuing Education Annual Meeting were successfully held online. The conference featured thematic speeches, in-depth case analyses, and scientific experience exchanges, covering various subtypes including Hodgkin lymphoma, diffuse large B-cell lymphoma, indolent lymphoma, extranodal lymphoma, plasma cell myeloma, and more. Core topics focused on the application of high-tech, optimization strategies for radiation therapy, new treatment methods, precise classification, and diagnostic techniques, providing participants with valuable insights into the latest advancements and future trends in the field. Notably, the conference brought together many internationally renowned experts who provided in-depth analyses and interpretations of lymphoma guidelines, evidence-based medicine, and clinical practice, offering excellent academic references. Professor Shunan Qi from the Cancer Hospital of the Chinese Academy of Medical Sciences, representing the organizing unit of this conference, gave an exclusive interview to "Oncology Frontier - Hematology Frontier" to provide a detailed interpretation of the conference's exciting content and advancements.
ASCO Highlights丨Professor Guohai Shi: Finding a Needle in a Haystack – The Journey of Exploring Biomarkers for Kidney Cancer

ASCO Highlights丨Professor Guohai Shi: Finding a Needle in a Haystack – The Journey of Exploring Biomarkers for Kidney Cancer

In recent years, significant progress has been made in the treatment of renal cell carcinoma (RCC). However, selecting the appropriate treatment strategy remains a critical challenge. Traditional tumor markers have limited predictive value in RCC, making the search for new and reliable biomarkers to guide treatment decisions a hot topic in RCC research. As one of the major oncology events of 2024, the ASCO Annual Meeting is set to take place soon. Oncology Outlook has invited Professor Guohai Shi from Fudan University Cancer Hospital to share the major research findings on kidney cancer biomarkers that will be presented at the conference.
ASCO Highlights丨Professor Guohai Shi: Finding a Needle in a Haystack – The Journey of Exploring Biomarkers for Kidney Cancer

ASCO Highlights丨Professor Guohai Shi: Finding a Needle in a Haystack – The Journey of Exploring Biomarkers for Kidney Cancer

In recent years, significant progress has been made in the treatment of renal cell carcinoma (RCC). However, selecting the appropriate treatment strategy remains a critical challenge. Traditional tumor markers have limited predictive value in RCC, making the search for new and reliable biomarkers to guide treatment decisions a hot topic in RCC research. As one of the major oncology events of 2024, the ASCO Annual Meeting is set to take place soon. Oncology Outlook has invited Professor Guohai Shi from Fudan University Cancer Hospital to share the major research findings on kidney cancer biomarkers that will be presented at the conference
ASCO China Voice丨Professor Nanlin Li: Efficacy and Safety Data of RC48 for Neoadjuvant Therapy in HER2-Positive Breast Cancer

ASCO China Voice丨Professor Nanlin Li: Efficacy and Safety Data of RC48 for Neoadjuvant Therapy in HER2-Positive Breast Cancer

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will take place in Chicago from May 31 to June 4. Led by Professor Nanlin Li from Xijing Hospital of the Air Force Medical University, a single-center, single-arm phase II clinical study focused on the efficacy and safety of the HER2-targeting antibody-drug conjugate (ADC) RC48 in the neoadjuvant treatment of HER2-positive breast cancer has disclosed its data. The study shows that although RC48 achieved lower pathological complete response rates (pCR) compared to traditional chemotherapy combined with targeted therapy, it effectively reduced tumor size rapidly, achieved moderate to significant remission, and had high safety with minimal toxicity. These findings provide a new option for neoadjuvant treatment of HER2-positive breast cancer and may expand the indications for domestically developed ADC drugs. This article reports the relevant data.
Big Data, New Discoveries—The Key Role of Radiation Therapy in MZL and MALT Treatment

Big Data, New Discoveries—The Key Role of Radiation Therapy in MZL and MALT Treatment

With the rapid development of medical technology, modern lymphoma treatment has become a key focus in the field of oncology. From May 25 to 26, the Modern Lymphoma Treatment Academic Conference and the 5th International Lymphoma Radiation Oncology Group (ILROG) Continuing Education Annual Meeting were successfully held online. The conference featured thematic speeches, in-depth case analyses, and scientific experience exchanges, covering various subtypes including Hodgkin lymphoma, diffuse large B-cell lymphoma, indolent lymphoma, extranodal lymphoma, plasma cell myeloma, and more. Core topics focused on the application of high-tech, optimization strategies for radiation therapy, new treatment methods, precise classification, and diagnostic techniques, providing participants with valuable insights into the latest advancements and future trends in the field. Notably, the conference brought together many internationally renowned experts who provided in-depth analyses and interpretations of lymphoma guidelines, evidence-based medicine, and clinical practice, offering excellent academic references. Professor Shunan Qi from the Cancer Hospital of the Chinese Academy of Medical Sciences, representing the organizing unit of this conference, gave an exclusive interview to "Oncology Frontier - Hematology Frontier" to provide a detailed interpretation of the conference's exciting content and advancements.